7033084312 P.01/03

RESPONSE UNDER 37 CFR 1.116
EXPRINTED PROCEDURE
EXAMINED GROUP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTN .: NANCY VOGEL

TO

In re Application of: ) Art Unit: 1805

CLASSEN, J.B. ) Examiner: VOGEL, N.

Serial No.: 08/104,529 ) Washington, D.C.

Filed: August 12, 1993 ) April 12, 1995

For: METHOD AND COMP- ) Docket No.: CLASSEN=1

OSITION FOR AN...

## SUPPLEMENTAL AMENDMENT AFTER FINAL REJECTION

COURTESY COPY VIA FACSIMILE - (703-308-4312)
Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

FAX CENTER RECEIVED

APR 1 2 1995

Sir:



**GROUP 1800** 

## IN THE CLAIMS

Cancel claim 15.

In claim 37, line 19, as amended on April 10, 1995, replace "before" with --after--.

Please amend claims 22 and 28 as follows:

20 2 (amended). The method of claim 21 wherein said further administration

comprises further administering to said mammal of at least 28 days of age but less than 175 days of age, at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen,

wherein said at least one dose comprises a total of at least 4 separate pharmaceutically acceptable doses of at least one pharmaceutically acceptable immunogen from the group consisting of a diphtheria/tetanus/pertussis immunogen, a hepatitis B immunogen, a hemophilus influenza immunogen, a measles/mumps/rubella immunogen, a polio immunogen, and a non-

96